Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

Based on the ChAdOx1 adenovirus viral vector platform also used in the successful Oxford coronavirus vaccine, forty healthy adults aged 18 to 55 will receive this new vaccine in order to assess side effects and determine how well it induces protective antibody and T cell responses.

Professor Sir Andrew Pollard, Director of the Oxford Vaccine Group, said:

‘The coronavirus pandemic has shown the importance of vaccines to defend populations from the threat caused by bacteria and viruses. Plague threatened the world in several horrific waves over past millennia, and, even today, outbreaks continue to disrupt communities. A new vaccine to prevent plague is important for them and for our health security.’

Probably the most well-known example of plague is the Black Death of the 1300s; this form of the bubonic plague was the biggest global pandemic in history and killed hundreds of millions of people worldwide.

Although for much of the world plague has been eliminated, cases do continue to occur annually in rural areas of Africa, Asia and even America.

There are three different types of plague: bubonic, pneumonic and septicaemic. If left untreated, the bubonic form has a 30 percent to 60 percent fatality rate and the pneumonic form is almost always fatal. Both bubonic and pneumonic plague can develop into a life-threatening infection of the blood called septicaemia.

From 2010 to 2015, there were 3,248 cases reported globally, including 584 deaths. A relatively recent epidemic in Madagascar saw 2,119 suspected cases and 171 deaths from August 2017 to November 2017.

Christine Rollier, Associate Professor of Vaccinology at the Oxford Vaccine Group, said:

‘Although antibiotics can be used to treat plague, many areas experiencing outbreaks are very remote locations. In such areas, an effective vaccine could offer a successful prevention strategy to combat the disease.’

Volunteers for the trial will receive expert follow up for 12 months, before the researchers begin evaluating the data in order to report their findings.

To find out more about the study, or to sign up, please visit: https://trials.ovg.ox.ac.uk/trials/plague

Similar stories

New survey launched to explore the acceptability of the Gonococcal Controlled Human Infection Model in UK men.

Researchers at the University of Oxford have launched a new mixed methods study to explore the acceptability of the Gonococcal Controlled Human Infection Model (GC-CHIM) in UK men.

Oxford Ebola vaccine manufactured and shipped in record time by SII

More than 40,000 doses of Oxford’s Ebola vaccine have been manufactured by SII (Serum Institute of India) in just 60 days and doses shipped to Uganda.

From running COVID-19 trials to researching respiratory diseases - Daniela Ferreira discusses her journey from Brazil to Oxford

Daniela Ferreira, Professor of Mucosal Immunity and Infection at the Oxford Vaccine Group, Department of Paediatrics, has so much enthusiasm for her work on respiratory infections and vaccinology, you would be very hard-pressed not to want her to succeed

Oxford to work with Brazil to establish clinical research hub

The University of Oxford and Brazilian Ministry of Health have announced a joint initiative to set up a global health and clinical research unit in Brazil led by Professor Sue Ann Clemens CBE.

Delayed second dose and third doses of the Oxford-AstraZeneca vaccine lead to heightened immune response

Research on the ChAdOx1 nCoV-19, also known as the Oxford-AstraZeneca vaccine, indicates that a long interval between first and second doses does not compromise the immune response after a late second dose.

Oxford University extends COVID-19 vaccine study to children

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.